Kim HS, Kang J, Hwang D, et al. - Researchers compared DP-DES [drug-eluting stents based on durable polymer] and BP (biodegradable polymer)-DES in patients with acute coronary syndrome (ACS), focusing on efficacy and safety of these in this investigator-initiated, randomized, open-label, adjudicator-blinded, multicenter, non-inferiority trial, named the HOST-REDUCE-POLYTECH-ACS trial. The goal was to confirm the non-inferiority of the DP-DES vs the BP-DES in such patients. Patient oriented composite outcome (POCO, a composite of all-cause mortality, non-fatal myocardial infarction (MI), and any repeat revascularization) at 12 months was the primary endpoint. Device oriented composite outcome (DOCO; a composite of cardiac mortality, target-vessel MI, or target lesion revascularization) at 12 months was the key secondary endpoint. At 12 months, the occurrence of POCO was reported in 5.2% and 6.4% in the DP-DES group and in the BP-DES group, respectively. A less frequent occurrence of DOCO was noted in the DP-DES group, mostly because of a decrease in target lesion revascularization. Findings demonstrated the non-inferiority of DP-DES to BP-DES, in terms of POCO at 12 months following index percutaneous coronary intervention (PCI), in ACS patients undergoing PCI.